adakveo
novartis europharm limited - crizanlizumab - anæmi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
linezolid "fresenius kabi" 2 mg/ml infusionsvæske, opløsning
fresenius kabi ab - linezolid - infusionsvæske, opløsning - 2 mg/ml
linezolid "orion" 600 mg filmovertrukne tabletter
orion corporation - linezolid - filmovertrukne tabletter - 600 mg
linezolid "sandoz" 600 mg filmovertrukne tabletter
sandoz a/s - linezolid - filmovertrukne tabletter - 600 mg
zyvoxid 2 mg/ml infusionsvæske, opløsning
pfizer aps - linezolid - infusionsvæske, opløsning - 2 mg/ml
nulojix
bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosuppressiva - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
linezolid "accord" 600 mg filmovertrukne tabletter
accord healthcare b.v. - linezolid - filmovertrukne tabletter - 600 mg
linezolid "accord" 2 mg/ml infusionsvæske, opløsning
accord healthcare b.v. - linezolid - infusionsvæske, opløsning - 2 mg/ml
linezolid "krka" 600 mg filmovertrukne tabletter
krka d.d. novo mesto - linezolid - filmovertrukne tabletter - 600 mg
linezolid "teva" 600 mg filmovertrukne tabletter
teva b.v. - linezolid - filmovertrukne tabletter - 600 mg